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Abstract
Background: DNA methylation has been found to associate with disease, aging and environmental exposure,
but it is unknown how genome, environment and disease influence DNA methylation dynamics in childhood.
Results: By analysing 538 paired DNA blood samples from children at birth and at 4–5 years old and 726 paired
samples from children at 4 and 8 years old from four European birth cohorts using the Illumina Infinium Human
Methylation 450 k chip, we have identified 14,150 consistent age-differential methylation sites (a-DMSs) at epigenome-
wide significance of p < 1.14 × 10−7. Genes with an increase in age-differential methylation were enriched in pathways
related to ‘development’, and were more often located in bivalent transcription start site (TSS) regions, which can silence
or activate expression of developmental genes. Genes with a decrease in age-differential methylation were involved in
cell signalling, and enriched on H3K27ac, which can predict developmental state. Maternal smoking tended to decrease
methylation levels at the identified da-DMSs. We also found 101 a-DMSs (0.71%) that were regulated by genetic variants
using cis-differential Methylation Quantitative Trait Locus (cis-dMeQTL) mapping. Moreover, a-DMS-associated genes
during early development were significantly more likely to be linked with disease.
Conclusion: Our study provides new insights into the dynamic epigenetic landscape of the first 8 years of life.
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Background
DNA methylation is the most extensively studied epigen-
etic mechanism. An individual’s DNA methylation profile
is not static but subject to dynamic changes induced by
genetic [1, 2], environmental [3, 4] and stochastic factors
during ageing. Although some age-related epigenetic
changes have been identified [5–9], how genetic and
environmental factors influence methylation-change with
ageing is not yet well understood.
To answer these questions, we performed an epigenome-
wide longitudinal DNA methylation study of 632 children
across four European population-based birth cohorts
participating in the MeDALL (Mechanisms of Develop-
ment of ALLergy) consortium epigenetic study [10] using
the Illumina Infinium HumanMethylation450 BeadChip
(HM450) array. We compared 269 children at ages 0 and
4/5 years, by investigating 538 paired samples of cord
blood and peripheral blood DNA, and another set of 363
children at ages 4 and 8 years (726 paired samples of
peripheral blood DNA). We first identified a set of overlap-
ping and consistent age-differential methylation sites (a-
DMSs) in each group and looked at their functions. Then
we linked genetic variation and maternal smoking during
pregnancy with the changes in these a-DMSs over time to
see how genetic and environmental factors regulate
dynamic changes in methylation. Finally, we investigated if
genes annotated to these a-DMSs were enriched for
disease-associated genes; we linked these a-DMSs to
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asthma, the chronic disease with the highest prevalence in
childhood.
Results
Identification of a-DMSs
We first applied differential methylation analysis on
439,306 cytosine-phosphate-guanine (CpG) sites that
passed our quality control (see Methods) in 538 paired
samples from the INMA (Spain) and EDEN (France) birth
cohorts (ages 0 and 4/5) and in 726 paired samples from
the BAMSE (Sweden) and PIAMA (Netherlands) birth
cohorts (ages 4 and 8), (Fig. 1, Additional file 1: Table S1).
The overall correlations of methylation levels between
two time points in the four birth cohorts are shown
in Additional file 2: Figure S1. In the pooled analysis
of all cohorts adjusting for cell-type-composition [11],
15,529 significant a-DMSs were identified in both age
groups surpassing the 5% Bonferroni corrected threshold
(P < 1.14 × 10−7) (Additional file 1: Figures S2 and S3). Of
these 15,529 a-DMSs, 9,704 (62.5%) showed a consistent
decrease in methylation with age (decrease in age-
differential methylation sites, da-DMSs), whereas 4,446
(28.6%) showed a consistent increase in methylation with
age (increase in age-differential methylation sites, ia-
DMSs). Only 1,379(8.9%) of the CpG sites showed oppos-
ite directions in their methylation changes between the
younger and older comparison sets (Additional file 1:
Table S2). The complete list of 14,150 consistent da-
DMSs and ia-DMSs, and their annotation, is presented in
Additional file 3. Comparing our a-DMS results with
those from two independent, paediatric, age-related
methylation studies [7, 8], we see more than 50% overlap
in the CpG sites identified (Additional file 1: Table S3).
We observed that some of our consistent da-DMSs were
located in clusters, probably reflecting age associated
differential methylated regions rather than one site.
The most significant ia-DMSs, cg01511232 (p0-4/5 =
7.92 × 10−148, p4-8 < 2.25x10
−308) and cg22398226 (p0-4/5
= 1.66 × 10−149, p4-8 = 5.09x10
−307) are located on the
chromosome 4q32.1, near the gene LRAT. Mutations in
this gene have been associated with early onset retinal dys-
trophy [12]. The top associated da-DMSs, cg16069986
(p0-4/5 = 6.28 × 10
−114, p4-8 < 2.25x10
−308) and cg163125
14(p0-4/5 = 1.67 × 10
−106, p4-8 < 2.25x10
−308) on chromo-
some 11q13.4 region were annotated in SHANK2.
Mutations in this SHANK2 synaptic scaffolding gene
have been associated with neurodevelopmental disor-
ders and autism [13].
Characterization of da-DMSs and ia-DMSs
We next examined the enrichment of the 9,704 da-
DMSs and 4,446 ia-DMSs in genomic regions and their
predicted roles in regulating gene expression using his-
tone modifications and chromatin state data from the
Roadmap Epigenomics Project [14]. ia-DMSs were situ-
ated in distinctly different functional domains compared
to da-DMSs, which is consistent with previous findings
[9, 15]. Thus, compared to all the CpG sites we tested,
ia-DMSs were enriched in CpG shores (Fig. 2a) and gene
bodies (Fig. 2b), while da-DMSs were enriched in open
seas, shelves, shores, intergenic regions and transcription
start site (TSS) 1500 regions. ia-DMSs were also
enriched in transcriptional repression histone modifica-
tion marker (H3K9Me3), while da-DMSs were depleted
for this marker (Fig. 2c). Both da-DMSs and ia-DMSs
were enriched in enhancers and bivalent enhancers
(Fig. 2d). ia-DMSs were also enriched in bivalent TSS
regions (Fig. 2d), which are thought to silence or
activate expression of developmental genes [16]. In
contrast, da-DMSs were enriched in H3K27ac, which
separates active from poised enhancers and predict
developmental state [17].
Fig. 1 Study design and structure of this paper. We collected cord
blood and peripheral blood samples from 632 children from four
European birth cohorts: INMA, EDEN, BAMSE and PIAMA. Differential
methylation analysis on different age groups resulted in 14,150
consistent age-differential methylation sites (a-DMSs). We then linked
the methylation change of these a-DMSs to genetics by cis-dMeQTL,
to environmental exposure from maternal smoking, and to diseases,
specifically asthma
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We next performed pathway analysis by GeneNetwork
[18] on genes located in close proximity to DMSs probes.
In total, 3559 genes were annotated to be located near ia-
DMSs probes and 7130 genes near the da-DMSs probes.
1940 of these genes were overlapping across the two
groups, suggesting complex regulation of these genes
during development. The pathway analysis of da-DMSs
specific genes using gene co-expression indicated enrich-
ment of Reactome pathways involved in cell signalling, in-
cluding signalling by nerve growth factors, platelet derived
growth factors, neurotrophin signalling and many others
(Additional file 4). The corresponding Mouse Genome
Informatics (MGI) phenotypes pointed to cell migration,
growth retardation and various abnormal tissue morph-
ologies. The ia-DMS specific genes were enriched for
developmental genes, axon guidance, regulation of insulin
secretion and energy metabolism. The enriched MGI phe-
notypes were related to neonatal and postnatal lethality.
This indicates that in early age methylation regulates the
activity of genes, involved in basic processes of develop-
ment and metabolism.
Next, we inspected methylation dynamics of some well-
known developmental genes and found a lot of CpGs sites
which were annotated to them, such as growth differenti-
ation factors(GDFs), Bone morphogeneic proteins(BMPs),
Wnt signalling pathway (Wnt) gene, Paired box genes(Pax)
and homeotic genes (Hox) gene etc. Among them, the 5′
HOXD cluster [19] that contains genes important for limb
development. The 5′ HOXD cluster consists of five genes
(HOXD9 to HOXD13). We found eight ia-DMSs with low
methylation status within the cluster (Additional file 1:
Table S4), seven of which were localized in CpG islands
encompassing the five promoters and three first exons. In
contrast, Meis homeobox 1 (cg12055515, MEIS1, P0-4/5 =
7.95 × 10−17, P4-8 = 1.77 × 10
−11), a limb development regu-
lator that forms complexes with both HOXD9 and
HOXD10 [19], displays a different methylation pattern.
Cg12055515 lies in the gene body ofMEIS1 and its methy-
lation level decreases during ageing (Additional file 1:
Table S5).
Genetic variation associates with longitudinal DNA
methylation changes
The availability of paired samples from four different
cohorts gave us the possibility to investigate the effect of
genetics on methylation dynamics in a longitudinal way.
We examined whether genetic variations were associated
with longitudinal DNA methylation changes in childhood
using cis-differential Methylation Quantitative Trait Locus
(cis-dMeQTL) mapping. We associated SNPs within
Fig. 2 Molecular enrichment of a-DMSs for regulatory features. Fold enrichment of 9,704 da-DMSs (blue bar) and 4,446 ia-DMSs (grey bar). a CpG
islands, shore, shelf and open sea. b Gene regions including: within 1.5 kb upstream of the transcription start site (TSS1500), the 5' untranslated
region (5′UTR), the first gene exon, the gene body, the 3' UTR or intergenic region. c Predicted gene expression regulatory regions based on
histone modifications derived from Roadmap epigenomics blood data. d Predicted chromatin state based on Roadmap epigenomics blood data.
DNase: DNase I hypersensitive site, Enh: Enhancers, EnhBiv: Bivalent enhancer, TssA: Active TSS, TSSBiv: Bivalent/poised TSS, Tx: Strong transcription,
TxWk: Weak transcription. The presented fold enrichments are from 1,264 samples by χ2 test and are relative to all 437,792 CpG sites tested (y-axis); *
1 × 10−3≤ P < 0.01, ** 1 × 10−6≤ P < 1 × 10-3, *** P < 1 × 10−6
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±250 kb of our 14,150 a-DMSs in GWAS data available
for 230 children from BAMSE and PIAMA in the 4–8
years-old comparison set for discovery and from 114 chil-
dren in the INMA 0–4/5 years-old comparison set for
replication (Additional file 1: Table S1). We discovered
7,316 SNP-CpG pairs on 866 aDMSs with significant cis-
dMeQTLs in the older comparison set (FDR < 0.05), and
3,534 SNP-CpG pairs (48.3%) were replicated in the youn-
ger comparison set (same direction of effects and nominal
P < 0.05). 113 potentially false-positive dMeQTLs were re-
moved due to SNP-under-the-probe effects [20]. The
remaining 3,421 (46.8%) SNP-CpG pairs are listed in
Additional file 5, consisting of 2734 SNPs regulating 101
a-DMSs (60 da-DMSs and 41 ia-DMSs) that changed with
age and showed methylation change was partly under gen-
etic control. To understand these dMeQTLs, we tested if
these 3,421 SNP-CpG pairs were MeQTLs at age 4 and
8 years cross-sectionally. Most SNP-CpG pairs showing
dMeQTL were significant MeQTLs when analysed cross-
sectionally at both ages (Additional file 3). The most sig-
nificant MeQTL rs7522439-cg00025357, which are on
chromosome 1p36.13, close to gene PADI3 . By checking
the BIOS QTL browser (http://genenetwork.nl/biosqtl-
browser/), we also found the significant cis-MeQTL
(P = 3.3 × 10−310) in methylation data from adult blood
DNA samples, which is line with the recent findings
that genetic effects on methylation levels are stable [21].
However, we also found three CpG sites cg00804078,
cg02872436 and cg14956327 which were annotated to the
DDO (D-aspartate oxidase) gene showing significant cis-
MeQTL, but did not show significant cis-MeQTL in the
BIOS QTL database. This may indicate an age specific
MeQTL effect since D-aspartate content in brain is
decreased during adulthood [22].
Furthermore, we compared the MeQTL-effect size at
ages 4 and 8 (Fig. 3a), and found that almost all effects
of genetic factors on methylation had the same direction
at both ages (3,348 SNP-CpG pairs; 97.9%), i.e., genetic
effects on methylation remained stable with ageing.
Among these 3,348 SNP-CpG pairs, 725 had a signifi-
cantly larger effect and 2,623 had a significantly smaller
effect at age 4 years than at age 8 (Fig. 3b, 1-sample pro-
portion test, P = 4.8 × 10−236). An example of this pattern
(Figs. 3c and d) is shown for the rs9320331_cg00804078
SNP-CpG pair in the DDO (D-aspartate oxidase) gene,
which showed a MeQTL at both ages 4 and 8
(Fig. 3e), with a stronger effect at age 8(beta = 0.058,
P = 1.3 × 10−13) compared to the effect at age 4 (beta
= 0.032, P = 2.7 × 10−6).
Maternal smoking during pregnancy associates with
longitudinal DNA methylation changes
Methylation has been found strongly associated with
maternal smoking during pregnancy [3]. Here we further
investigated whether methylation changes of the 14,150
a-DMSs between the 0–4/5 and 4–8 years-old compari-
son sets were associated with maternal smoking during
pregnancy. In total, we found eight significant a-DMSs
in the younger set and one in the older set (FDR < 0.05,
Additional file 1: Table S6) associated with maternal
smoking. These nine CpG sites mapped to five genes,
ITGA11, OR5B3, VWF, RCBTB1 and CREB5 and one
pseudogene HNRNPA3P1. The most significant associ-
ation was for the methylation change of cg09836827 at
the VWF gene (Von Willebrand Factor), a protein-
coding gene crucial for haemostasis. Both VWF and
ITGA11 (integrin alpha 11) are involved in regulating
cell-substrate adhesion. Interestingly, all nine significant
CpG sites belonged to the da-DMS group, and the asso-
ciation of maternal smoking with methylation changes
was always negative (Additional file 1: Table S6). This
means that the methylation decrease was consistently
larger in the children exposed to smoke in utero com-
pared to the non-exposed. Fig. 4a and Additional file 2:
Figure S4 show that maternal smoking during pregnancy
was associated with a stronger, decreasing effect on
methylation change of cg09836827 (VWF) in those
children. To underpin this, we further checked the
directions of effect of all nominally significant a-DMSs
(P < 0.05) and found that methylation changes tended to
be negatively associated with maternal smoking between
0 and 4/5 years (Fig. 4b) and, moreover, that 721/971
(74.2%) a-DMSs showed a stronger decrease in methyla-
tion levels from 0 to 4/5 years (Additional file 1: Table
S7). In summary, we found that maternal smoking ex-
posure tended to more strongly decrease methylation
levels at the identified da-DMSs.
DNA methylation changes related to disease
development
Early children development is considered to be the most
important phase in life and also of great vulnerability to
negative influences. We found that many top associated
a-DMSs, and their annotated gene were linked to dis-
eases, such as SHANK2 (cg16069986 and cg16312514)
which is related to autism, and CSRP3 (cg05895618)
which is linked to cardiomyopathy. We hypothesised
that these a-DMSs annotated genes are crucial for the
growth, and dysregulation of gene expression and even-
tually lead to disease development. Therefore, we further
investigated if genes containing a-DMSs were more
likely to be associated with disease by studying the en-
richment of genes on our list (Additional file 1) in the
catalogue of disease-associated genes provided by the
Clinical Genomic Database [23]. Indeed, we found that
genes containing a-DMSs were more likely to be
disease-related (16.9% compared with 14.0%, P = 4.9 × 10
−6, Fisher’s exact test) (Additional file 1: Table S8). This
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Fig. 3 (See legend on next page.)
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might indicate a link between age-related methylation
changes and disease.
We then investigated the associations of the a-DMSs
with asthma, the most common chronic pulmonary dis-
ease in childhood, and the focus of our MeDALL study
[10]. Since early-life exposures strongly influence asthma
development, and may affect DNA methylation [24], we
hypothesized that dynamic methylation changes occurring
specifically in early childhood might be associated with
asthma. We tested the association of our 14,150 a-DMSs
with asthma at age 4/5 and 8 years using the MeDALL
asthma definition [25]. Three CpG sites were significantly
associated (FDR < 0.05) with asthma at age 4: cg22971191
in SLC10A2 (solute carrier family 10 (sodium/bile acid
cotransporter) member 2), cg18515031 in C10orf104
(chromosome 10 open reading frame 104) and cg05712073
in ZNF384 (Zinc Finger Protein 384). We also found one
significant (FDR < 0.05) CpG site, cg02977254 in C11orf63
(Chromosome 11 Open Reading Frame 63), to be associ-
ated with asthma at age 8 (Additional file 1: Table S9).
Discussion
This study offers insight into the dynamic epigenetic land-
scape of the first 8 years of life. We report a large number
of DNA methylation changes that are consistent between
both our age range comparisons (0-4/5 years and 4–8
years). These changes with increasing age (da-DMSs and
ia-DMSs) have distinct, only partly overlapping, genetic
localizations and functional annotations. The enrichment
of a-DMSs in gene bodies and in enhancer regions suggest
that longitudinal changes in DNA methylation are not
only acting as transcription repressors, but may also act as
buffers to stabilize decisions by transcription factors, en-
suring precise and robust transcription [26]. Importantly,
we also demonstrate that ia-DMSs occur preferentially at
developmental genes (e.g., 5′ HOXD) cluster and are
located at bivalent chromatin domains. These chromatin
domains appear to be able to repress or activate epigenetic
modifications, and are thought to be important during im-
printing and development. We focused on consistent
methylation changes that are present between ages 0 to 4
as well as 4 to 8 years, and suggest that further analyses
Fig. 4 The effect of maternal smoking on methylation change. a The
effect of maternal smoking on methylation change of cg09836827 (VWF)
in the age 0–4/5 group. Maternal smoking shows an enhanced effect on
decreasing methylation levels since the decrease from age 0 to age
4/5 years old of cg09836827 in the exposed group is significantly
larger compared to the non-exposed group. b Density plot of
effect size of all nominally significant a-DMSs (P < 0.05) with maternal
smoking. In the age 0–4/5 group, methylation changes tend to be
negatively associated with maternal smoking since there are more
negatively associated a-DMSs. In the age 4–8 group, there are similar
numbers of negatively- and positively associated sites
(See figure on previous page.)
Fig. 3 Genetic variation associated with longitudinal DNA methylation changes by cis-dMeQTL study. a The effect sizes of MeQTL at age 4 years against
those at age 8 years of 3421 SNP-CpG pairs in the age 4-8 group. Almost all the dots lie in the first and third quadrants, suggesting that the effect size
of genetic factors on methylation from most of the SNP-CpG pairs followed the same direction at both ages. Blue dots represent SNP-CpG pairs with a
significantly weaker effect size at age 4 than at age 8, whereas green dots represent a stronger effect, and red dots represent a different direction of
effect. b Bar plot of 3421 SNP-CpG pairs. There are 725 SNP-CpG pairs showing a weaker effect at age 4 than age 8 (blue bar), 3,348 SNP-CpG pairs
showing stronger effect (green bar) and 73 SNP-CpG pairs showing a different effect (red bar). c Boxplot of dMeQTL of rs9320331-cg00074818. 181 PIAMA
samples have been used to illustrate this dMeQTL. d Regional dMeQTL association of cg00074818 results for the age 4–8 group. Plots were generated
using LocusZoom [48]. The LD estimates are color-coded as a heatmap from dark blue (0≥ r2 > 0.2) to red (0.8≥ r2 > 1.0) Regional plot shows-log10P of
all SNPs surrounding SNP rs9320331, and the degree of linkage disequilibrium between all SNPs and lead SNP rs9320331. SNPs with lower P-values span
DDO and SLC22A18 genes within a recombination boundary. e Boxplot of MeQTL of rs9320331-cg00074818 at age 4 and age 8 cross-sectionally
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using even shorter time periods (i.e., infancy) may reveal
further insight into the epigenetic association with specific
developmental periods of a child. For the first time, we
have linked genome-wide genetic variants with longitu-
dinal methylation changes by performing cis-dMeQTL
analysis. We find that 0.71% (101/14150) of the differen-
tially methylated CpG sites are regulated by genetic
variation, which is compatible with genetic control over
epigenetic plasticity. In most cases, MeQTL were more
pronounced at age 8 than at age 4, indicating stronger
genetic regulation later in childhood, and possibly linking
genetic regulation of methylation with ageing. Zooming
in on one dMeQTL, rs9320331-cg00804078 located on
chromosome 6q21 close to DDO gene (Fig. 3), we
observed relationships between this SNP, gene expression
and methylation by combining our data with public data
(Additional file 2: Figure S5). Methylation of cg00804078
was reported to be negatively correlated with DDO
expression in 1,264 monocyte samples [9], while SNP
rs9320331 has been detected as an eQTL of DDO mRNA
in whole blood27 and other tissues [27]. The expression of
the DDO enzyme has been reported to control the rate of
brain-ageing processes by decreasing D-aspartate levels
[28]. Therefore, a plausible mechanism for the observed
MeQTL is that SNPs regulate the expression of DDO
through DNA methylation to ultimately control the rate
the brain ages. In our data, we observed a significantly
lower methylation of cg00804078 from age 4 to 8, contrib-
uting to higher DDO expression and lower D-aspartate
levels, and corroborating earlier findings of lower D-
aspartate levels with ageing [29]. Moreover, we did not
observe significant cis-MeQTL of cg00804078 in adult
data by checking BIOS QTL browser. It may indicate that
epigenetic mediation of genetic risk [30] for DDO expres-
sion is age specific and only plays a role in childhood.
To assess the role of an important environmental factor,
we examined longitudinal changes in DNA methylation
associated to maternal smoking during pregnancy and
found association with decreasing methylation levels from
birth up to age 4/5. Since it has been suggested that
decreasing methylation is associated with ageing [6], our
findings may indicate that maternal smoking during preg-
nancy has an immediate effect on ageing by decreasing
methylation levels. However, we did not find this “decreas-
ing methylation” effect in our 4–8 year-old set. This shift
may indicate that the in utero effect of maternal smoking
is most crucial during the first years of life. We further
tested the effect of smoking on Horvath’s “epigenetic
clock” [5], which predicts age based on DNA methylation
data and statistical learning, but found no significant effect
(Additional file 2: Figure S6). This may be because the
“epigenetic clock” was trained on adult samples, making it
less accurate for age predictions based on DNA methyla-
tion in children (Additional file 2: Figure S7).
The DOHAD (Developmental Origins of Health and Dis-
ease) hypothesis proposes that early human development
affects the risk of chronic, non-communicable diseases in
later life [31]. Early life development may be expressed in
epigenetic mechanisms, such as DNA methylation, and this
may have long-lasting effects over an individual’s life. We
reasoned that the set of a-DMSs that change in the first
8 years of life could be used to test for enrichment with dis-
ease genes. One interesting observation that came out of
this analysis is that childhood a-DMS-genes were more
likely to be disease-linked. We therefore tested the associ-
ation of identified 14150 a-DMSs with asthma, which often
starts in early life and is the most prevalent chronic disease
in childhood. We identified four a-DMSs associated with
asthma at ages 4 and 8, a finding that warrants replication.
We propose that future studies could assess the association
of a-DMSs with other chronic, non-communicable diseases
originating in early childhood.
A major strength of our study is the combination of four
different European birth cohorts of general population
samples. Although children from more highly educated
parents may be overrepresented in our study [32], our
study represents a reasonable representation of European
populations, forming a large dataset with good statistical
power. Furthermore, the paired sample approach enables
conclusions on longitudinal changes, and we specifically
focused on childhood ageing to complement the focus on
adult ageing populations in the literature.
However, our study had some limitations: the HM450
platform only covers 1.6% of all methylation sites [33], and
the design of HM450 may be biased towards CpG-richer
regions of the genome. DNA was derived from different
blood cell types: cord blood at age 0 versus peripheral
blood at older ages; this could be a potential confounder.
We therefore applied a cell-type correction [11] and only
used findings consistent over the two comparison sets to
support our conclusions.
Conclusions
In this research, we observed dynamic DNA methylation
changes in the first 8 years of life, with increasing or de-
creasing a-DMSs having specific functional annotations
and genomic localizations. We describe that a subset of
these a-DMSs are under genetic control, and report how
maternal smoking affects DNA methylation changes in
early life. Finally, we provide evidence that the set of
genes annotated to a-DMSs is enriched for disease
development, and specifically show 4 CpG sites to be as-
sociated with asthma in the first 8 years of life.
Methods
Study population
All DNA samples were obtained from the MeDALL
epigenetics study, which covers four cohorts and was
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designed to investigate the development of asthma and
allergy using a paired case-cohort design. We firstly ran-
domly select paired samples at ages 0 and 4/5 years and
age 4 and 8 years, and then added more asthma cases.
This design resulted in an enrichment of subjects with
asthma. The prevalence of asthma at age 4 and age 8 in
all MeDALL samples are 25 and 20% respectively. Since
the aim of our study was to investigate methylation in
childhood ageing independent of disease status, we only
selected the random samples. In total, we had 1,622
paired samples from the four European birth cohorts:
BAMSE [34], EDEN [35], INMA [36] and PIAMA [32].
After random sample selection, 1,264 paired samples
were used in the analysis. The prevalence of asthma at
age 4 and age 8 in all random samples are 13 and 11%,
respectively. The basic characteristics of the participants
are given in Additional file 1: Table S1.
DNA extraction, bisulphite treatment and DNA
methylation measurement
In the MeDALL study, cord blood samples and periph-
eral blood samples were collected from all consenting
cohort participants and DNA was extracted using the
QIAamp blood kit (Qiagen or equivalent protocols),
followed by precipitation-based concentration using
GlycoBlue (Ambion). DNA concentration was deter-
mined by Nanodrop measurement and Picogreen quan-
tification. 500 ng of DNA was bisulphite-converted
using the EZ 96-DNA methylation kit (Zymo Research),
following the manufacturer’s standard protocol. After
verification of the bisulphite conversion step using
Sanger Sequencing, genome-wide DNA methylation was
measured using the Illumina Infinium HumanMethyla-
tion450 BeadChip. After normalization of the concentra-
tion, the samples were randomized to avoid batch
effects, and all paired samples were hybridized on the
same chip. Standard male and female DNA samples
were included in this step as control samples.
Quality control and pre-processing of microarray data
DNA methylation data were pre-processed in R with the
Bioconductor package Minfi [37], using the original
IDAT files extracted from the HiScanSQ scanner. We
had a total of 1,748 blood samples from four birth co-
horts in the MeDALL epigenetics study. Samples that
did not provide significant methylation signals in more
than 10% of probes (detection P = 0.01) were excluded
from further analysis. Samples were also excluded in
cases of low staining efficiency, low single base extension
efficiency, low stripping efficiency of DNA from probes
after single base extension, poor hybridization perform-
ance, poor bisulphite conversion and high negative con-
trol probe staining. Further, we used the 65 SNP probes
to check for concordances between paired DNA samples
from the sample individual and assessed the methylation
distribution of the X-chromosome to verify gender.
Paired samples with Pearson correlation coefficients <0.9
were regarded as sample mix-ups and were excluded from
the study. In total, we excluded 16 samples due to poor
quality and 24 samples due to apparent sample mix-up. In
probe filtering [38], we excluded probes on sex chromo-
somes, probes that mapped on multi-loci, the 65 random
SNPs assay and probes that contained SNPs at the target
CpG sites with a minor allele frequency >10%. The allele
frequencies of a list of SNPs were obtained from 1000
Genomes, release 20110521 for CEU population. Finally,
we implemented “DASEN” [39] to perform signal correc-
tion and normalization. After quality control, 1,708 sam-
ples and 439,306 autosomal probes remained. From these,
we selected 1,264 samples in pairs from the population of
randomly selected children for further analysis.
Differential methylation analysis
Methylation levels (beta values, β) at a given CpG site
were derived from the ratio of the methylated probe in-
tensity to overall intensity (sum of methylated and
unmethylated probe intensities): β is equal to M/(U +M
+ α), where M is the intensity of the methylated probe,
U is the intensity of the unmethylated probe, and α is
the constant offset with the default value of 100. To
remove bias in methylation profiles due to technical
variation, we implemented a correction procedure based
on 613 negative control probes [40] present in HM450K
arrays because these negative control probes did not re-
late to biological variation. First, we implemented princi-
pal component analysis (PCA) on control probe data
according to the method proposed by Zhang et al. [41].
Then, we permuted the control probe data 10000 times
and applied PCA to each of these permuted datasets.
We then selected principal components with a P-value
defined to get the P(number of var(random pc)>var(pc))/(number of
permutations) < 10
−4. The methylation data for each CpG
were the residuals from a linear model incorporating the
five significant principal components that reflected tech-
nical variation. We adjusted the residuals by cohort, gen-
der, bisulphite conversion kit batch number, position on
the array and the percentage of monocytes, B cells, NK
cells, CD4+ T cells, CD8+ T cells and granulocytes
predicted by Houseman et al’s algorithm [11]. In the
age-differential-methylation analysis, the significant
methylation differences of CpG Sites between two age
groups (ages 0–4/5 years and ages 4–8 years) were iden-
tified by fitting a robust linear regression model. For the
maternal smoking analysis, smoking during pregnancy
was defined as: the mother was smoking in the last
trimester of her pregnancy. The detailed definition of
maternal smoking for each cohort can be found in refer-
ence [3]. Additional variables included in the final robust
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linear model for maternal smoking analysis were mater-
nal age, parity and maternal education.
Genotyping, MeQTL and dMeQTL
Genotype data from the individual cohorts were imputed
to reference data of the 1000 Genomes’ CEU panel (release
March 2012). Detailed information on the genotyping of
BAMSE, INMA and PIAMA has already been published
[42]. Subsequent quality control removed SNPs with minor
allele frequency (MAF) <0.01, those with Hardy Weinberg
equilibrium P < 1x10−6, genotype call rate <0.95, the mini-
mum MACH R2 measure to include SNPs (rsq < 0.3) for
BAMSE data and Info score < 0.3 for PIAMA and INMA
data. All the genotypes were aligned to the GIANT release
of 1000G to facilitate further data integration and meta-
analysis by genotype Harmonizer 1.4.9 [43]. We had geno-
type data for 114 INMA samples, age 0-4/5 years, and for
181 PIAMA and 49 BAMSE samples, age 4–8 years.
The dMeQTL and MeQTL analysis was performed
using the R package MatrixEQTL [44] using an additive
linear model. To remove the effect of extreme outliers, we
trimmed the methylation set using: (25th percentile
-3*IQR) and (75th percentile + 3*IQR), where IQR = inter-
quartile range. SNPs were included in the cis-analysis if
they were located within 250 kb of the methylation probe
under consideration. The methylation differences between
two time points were used as molecular phenotype for
dMeQTL study. The fixed-effect-model based on the in-
verse standard error was utilized for meta-analysing
BAMSE and PIAMA dMeQTL and MeQTL results at age
4–8 by using METAL [45]. The BAMSE and PIAMA
samples from the 4–8 years-old comparison set were used
as discovery cohorts, and the INMA samples from the
younger comparison set were used as replication. The
SNP-CpG pairs were considered as significant dMeQTL
in the 4–8 years-old comparison set if the P-value after
FDR correction was <0.05 and if the P-value was <0.05 in
the replication study in the 0–4 years-old group. We
filtered the cis-meQTLs effects by removing SNP-CpG
pairs for which the same SNP was also located in the
probe, or for which the SNP was outside the probe but in
linkage disequilibrium (LD) (r2 > 0.2) with a SNP inside
the probe. We tested for LD between SNPs pairs by using
1000 Genomes’ CEU data [46].
Functional annotation analysis
For molecular enrichment analysis, CpG sets were anno-
tated by the Illumina HM450 manifest file (version 1.2).
Annotations used were classified as gene related (TSS1500
and TSS200, regions from-1500 to–200 and-200 to the
transcriptional start site, respectively; 5′ UTRs; first exons;
gene bodies; 3′ UTR and intergenic (no gene annotation))
or CpG island-related (islands shores (0 to 2 kb flanking
islands), shelves (2 to 4 kb flanking islands) and open sea
(>4 kb from islands)). All 3,091 CpH sites were excluded
in the enrichment analysis, leading to 437,792 CpG sites
for the enrichment test. In addition, the epigenome Road-
map annotation was created by overlapping the histone
marks and chromatin states for the 27 blood cell-types an-
notated in the epigenome Roadmap project with the CpG
sites interrogated by the HM450 array. The raw annotation
was retrieved from the Epigenome Roadmap web portal
(http://egg2.wustl.edu/roadmap/web_portal/index.html).
The mark states were combined over the 27 blood-related
types by taking a state as present if it was in at least 1 of
the 27 blood-related measurements.
In pathway and gene-set analysis of a-DMSs, we
used the loci and gene definitions predicted in
GREAT (Genomic Regions of Annotations Tool) [47]
that assigns biological meaning to cis regulatory
regions (CpG sites) using the single nearest gene as-
sociation rule within a 100 kb window. We used Gen-
eNetwork (http://129.125.135.180:8080/GeneNetwork/
pathway.html) [18] for pathway analysis of a-DMSs.
Methylation age and disease analysis
For the Horvath Age predictor, methylation age was deter-
mined in all cohorts using the online calculator (https://
labs.genetics.ucla.edu/horvath/dnamage/). For the disease
analysis, genes were linked to a disease based on the
Clinical Genomic Database [23] (http://research.nhgri.nih.-
gov/CGD/download/, last accessed on Feb 27 2016). Age-
related gene sets were annotated by the Illumina HM450
manifest file (version 1.2). For asthma analysis, we used
the full MeDALL data at age 4/5 years and 8 years (asthma
cases and population-based controls) to investigate the as-
sociations between CpG methylation and asthma status.
The basic characteristics of participants included in the
asthma study are listed in Additional file 1: Table S10. The
final robust regression model was as follows: methylation
levels (corrected by 5PC of control probes) ~ asthma + co-
variables + cell counts. The co-variables included were
cohorts, gender, bisulphite conversion kit batch number,
duration of the 450 K assay, position on the array and cell
count percentages of monocytes, B cells, NK cells, CD4+
T cells, CD8+ T cells and granulocytes predicted by
Houseman et al’s algorithm [11].
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